Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
In the current study, Doctor Thomas Rix and colleagues from Aalborg University Hospital in Denmark, set out to examine the hypothesis that a negative association exists between the development of AF and consumption of n-3 PUFA. “Since AF is present in over six million people in Europe and associated with considerable morbidity, mortality and economic costs, preventing AF by achievable dietary changes would be of major public interest,” said Dr. Rix.
“The 13% observed lower risk of AF seen at moderate intakes of marine n-3 PUFA compared with low intakes may be related to a reduction in ischemic heart disease and anti-inflammatory effects in addition to direct anti arrhythmic effects,” said Dr. Rix. He noted that in one study, treatment with 1.8g n-3PUFA/day in patients with low intakes of fish resulted in prolongation of the atrial effective refractory period and less inducible AF, both in subjects with AF (8) and subjects without AF (10).
Scientific Programme Online
© 2017 European Society of Cardiology. All rights reserved